AR016817A1 - Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento - Google Patents

Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento

Info

Publication number
AR016817A1
AR016817A1 ARP980104002A ARP980104002A AR016817A1 AR 016817 A1 AR016817 A1 AR 016817A1 AR P980104002 A ARP980104002 A AR P980104002A AR P980104002 A ARP980104002 A AR P980104002A AR 016817 A1 AR016817 A1 AR 016817A1
Authority
AR
Argentina
Prior art keywords
compounds
alkyl
chloro
urea
aryl
Prior art date
Application number
ARP980104002A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9717178.9A external-priority patent/GB9717178D0/en
Priority claimed from GBGB9807756.3A external-priority patent/GB9807756D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR016817A1 publication Critical patent/AR016817A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un derivado de fenilurea o feniltiourea que tiene la formula (I) donde: X e Y representan independientemente CH o nitrogeno, con lacondicion de que X e Yno representen ambos CH; Z representa oxígeno o azufre; R1 representa alquilo C1-6, alquenilo C2-6 o alcoxi C1-6, pudiendo estar cualquiera de ellosopcionalmente substituidos; halogeno, R7CO- o NR8R9CO-; R2, R3, R4, R5 y R6 representan independientemente alquilo C1-6, alquenilo C2-6, alcoxi C1-6, oalquiltio C1-6, pudiendo estar cualquiera de ellos opcionalmente substituido; hidrogeno, halogeno, nitro, ciano, ariloxi, arilo alquiloxi C1-6, arilo alquiloC1-6, R7CO-, R7SO2NH-, R7CON(R10)-, NR8R9CO-, COOR8 o heterociclilo; con la condicion de que por lo menos uno de R2, R3, R4, R5 y R6 sea distinto de hidrogeno;o un par adyacente de R2, R3, R4, R5 y R6 conjuntamente con los átomos de C a los cuales están unidos forman un anillo carboxílico o heterocíclico substituido;R7 es alquilo C1-6 o arilo; R8 y R9 representan independientemente hidrogeno, alquilo C1-6, arilo o arilo C1-6 alquilo; R10 es hidrogeno o alquilo C1-6; y n es0, 1, 2, 3 o 4; o una sal farmacéuticamente aceptable del mismo; con la condicion de que le compuesto no sea: (a) N-1-isoquinolinil-N-(1-metil-1H-indol-5-il)urea; (b) N-(3-cloro-4-trifluormetilfenil)-N-4-quinolinilurea; (c) N-(3-cloro-4-trifluormetilfenil)-N-(5-nitro-4-quinolinil)urea; (d) N-(3,4,5-trimetoxifenil)-N-(7-cloro-4-quinolinil)urea; (e) N-(4-metoxifenil)-N-(7-cloro-4-quinolinil)urea; o (f) N-(4-clorofenil)-N-(7-cloro-4-quinolinil)urea. Procedimiento parasu preparacion, biblioteca de compuestos, compuestos intermediarios, composicion farmacéutica, método de tratamiento y uso de dichos compuestos para lamanufactura de un medicamento. Los derivadosde fenilurea o feniltiourea son antagonistas no peptídicos del receptor HFGAN72 humano. En particular, estoscompuestos son de uso potencial en el tratamiento de la obesidad, incluyendo la obesidad que se observa en los pacientes con diabetes de tipoII (que nodependen de insulina) y/con desordenes de sueno.
ARP980104002A 1997-08-14 1998-08-12 Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento AR016817A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9717178.9A GB9717178D0 (en) 1997-08-14 1997-08-14 Compounds
GBGB9807756.3A GB9807756D0 (en) 1998-04-08 1998-04-08 Compounds

Publications (1)

Publication Number Publication Date
AR016817A1 true AR016817A1 (es) 2001-08-01

Family

ID=26312063

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104002A AR016817A1 (es) 1997-08-14 1998-08-12 Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento

Country Status (7)

Country Link
US (1) US6410529B1 (es)
EP (1) EP1003737A1 (es)
JP (1) JP2001515075A (es)
AR (1) AR016817A1 (es)
AU (1) AU8741198A (es)
CA (1) CA2300178A1 (es)
WO (1) WO1999009024A1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
IL128994A (en) 1996-09-25 2004-12-15 Zeneca Ltd History of quinoline and naphthyridine and their salts, processes for their preparation, pharmaceutical preparations containing them and their use as medicines
US5935814A (en) * 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) * 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6653086B1 (en) 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
AU4037799A (en) 1998-05-08 1999-11-29 Smithkline Beecham Plc Phenylurea and phenylthio urea derivatives
US6420563B1 (en) 1998-07-31 2002-07-16 Arena Pharmaceuticals, Inc. Small molecule modulators of G protein-coupled receptor six
WO2000037434A1 (fr) * 1998-12-22 2000-06-29 Mitsubishi Chemical Corporation Derives d'amide
ATE241345T1 (de) 1999-02-12 2003-06-15 Smithkline Beecham Plc Neue verwendung von orexinrezeptorantagonisten
WO2000047576A1 (en) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
EP1144409B1 (en) 1999-02-12 2004-11-17 SmithKline Beecham plc Phenyl urea and phenyl thiourea derivatives
DE60013250T2 (de) * 1999-02-12 2005-09-08 Smithkline Beecham P.L.C., Brentford Phenylharnstoff- und Phenylthioharnstoffderivate als Orexinrezeptorantagonisten
CN1364167A (zh) * 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
KR20020029419A (ko) * 1999-07-07 2002-04-18 다비드 에 질레스 퀴나졸린 유도체
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
ES2331050T3 (es) * 1999-09-29 2009-12-21 Nerviano Medical Sciences S.R.L. Metodos para creacion de una biblioteca de compuestos e identificacion de modelos y ligandos quimicos lideres para moleculas diana.
MXPA02004366A (es) 1999-11-05 2002-11-07 Astrazeneca Ab Derivados de quinazolina como inhibidores vegf.
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
BRPI0109200B8 (pt) 2000-03-14 2021-05-25 Actelion Pharmaceuticals Ltd compostos e composições farmacêuticas
AU779266B2 (en) 2000-05-11 2005-01-13 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
EP1289955B1 (en) * 2000-06-16 2005-04-13 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
ATE413394T1 (de) 2000-06-24 2008-11-15 Astrazeneca Ab Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten
WO2002002534A1 (en) * 2000-07-03 2002-01-10 Astrazeneca Ab Quinazolines with therapeutic use
CN1482912A (zh) * 2000-12-21 2004-03-17 ���鹫˾ 杂芳基脲神经肽yy5受体拮抗剂
US6946476B2 (en) 2000-12-21 2005-09-20 Schering Corporation Heteroaryl urea neuropeptide Y Y5 receptor antagonists
EP1956020A3 (en) 2001-05-05 2008-08-20 Smithkline Beecham Plc 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity
ES2266549T3 (es) 2001-06-28 2007-03-01 Smithkline Beecham Plc Derivados de n-aroil-amina ciclicos como antagonistas del receptor de orexina.
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
RU2005103398A (ru) 2002-07-09 2006-06-27 Актелион Фармасьютикалз Лтд. (Ch) Производные 7,8,9,10-тетрагидро-6h-азепино-, 6,7,8,9-тетрагидропиридо-и 2,3-дигидро-2h-пирроло-[2,1-b]-хиназолинона
CN1681789A (zh) * 2002-09-17 2005-10-12 埃科特莱茵药品有限公司 1－吡啶－4－基－脲衍生物
WO2004033418A2 (en) 2002-10-11 2004-04-22 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
AU2003295158A1 (en) * 2002-12-24 2004-07-22 Biofocus Plc Compound libraries of 1,3,5-substitute indazole derivatives as compounds for targetting compounds capable of binding to the g-protein coupled receptor
GB0230195D0 (en) * 2002-12-24 2003-02-05 Biofocus Plc Compound Libraries
EP1611128A2 (en) * 2003-03-28 2006-01-04 Pharmacia & Upjohn Company LLC Positive allosteric modulators of the nicotinic acetylcholine receptor
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
AU2004233941A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
DE602004011204T2 (de) 2003-04-28 2008-12-24 Actelion Pharmaceuticals Ltd. Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
NZ550216A (en) 2004-03-01 2009-08-28 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
JP2007532484A (ja) 2004-03-16 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1799669A1 (en) * 2004-10-13 2007-06-27 Merck Patent GmbH Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US7501395B2 (en) 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
JP2009543785A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド 架橋ジアゼパンオレキシン受容体アンタゴニスト
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
WO2008101030A1 (en) * 2007-02-13 2008-08-21 The Regents Of The University Of California Methods for amplifying steroid hormone effects
JP2010527924A (ja) 2007-05-18 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト
PL2152690T3 (pl) 2007-05-23 2012-06-29 Merck Sharp & Dohme Pirydylo piperydynowi antagoniści receptora oreksyny
CA2687230A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
US20110039857A1 (en) * 2008-04-30 2011-02-17 Hamed Aissaoui Piperidine and pyroolidine compounds
CA2745420A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
MY160468A (en) * 2009-02-11 2017-03-15 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
JP2012524760A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド オレキシンアンタゴニストとして使用される３−アザビシクロ［４．１．０］ヘプタン
JP2013502448A (ja) 2009-08-24 2013-01-24 グラクソ グループ リミテッド オレキシンアンタゴニストとして用いられるピペリジン誘導体
US20120149723A1 (en) 2009-08-24 2012-06-14 Romano Di Fabio 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
RU2605549C2 (ru) * 2010-04-02 2016-12-20 Синомикс, Инк. Производные 3-карбокси-4-аминохинолина, полезные как модификаторы сладкого вкуса
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
CA2803387C (en) * 2010-07-29 2017-12-05 Bayard R. Huck Cyclic amine azaheterocyclic carboxamides
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
EP2742026B1 (en) 2011-08-12 2016-10-05 Senomyx, Inc. Sweet flavor modifier
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
MX2017005931A (es) 2014-11-07 2017-06-30 Senomyx Inc Acidos 4-amino-5- (ciclohexiloxi) quinolina-3-carboxilicos sustituidos como modificadores del sabor dulce.
RU2731095C2 (ru) 2016-03-17 2020-08-28 Ф. Хоффманн-Ля Рош Аг Производное 5-этил-4-метил-пиразол-3-карбоксамида, обладающее активностью агониста taar
US20220151991A1 (en) 2019-03-14 2022-05-19 Board Of Regents, The University Of Texas System Small molecule grb2 stabilizers for ras map kinase inhibition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009020A (en) * 1975-05-06 1977-02-22 Amchem Products, Inc. Method of regulating plant growth
US5552411A (en) * 1995-05-26 1996-09-03 Warner-Lambert Company Sulfonylquinolines as central nervous system and cardiovascular agents
US5731315A (en) * 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
AU726637B2 (en) * 1996-12-13 2000-11-16 Aventis Pharmaceuticals Inc. Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds

Also Published As

Publication number Publication date
WO1999009024A1 (en) 1999-02-25
AU8741198A (en) 1999-03-08
JP2001515075A (ja) 2001-09-18
US6410529B1 (en) 2002-06-25
CA2300178A1 (en) 1999-02-25
EP1003737A1 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
AR016817A1 (es) Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
CO5261605A1 (es) Compustos farmaceuticos
HUP0104497A2 (hu) Benzamidszármazékok, előállításuk, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PE20040655A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen
ES2037752T3 (es) Utilizacion de un derivado de benzoxazol y su procedimiento de preparacion.
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
BR9608048A (pt) Compostos de benzimidazol, composições farmacêuticas contendo os compostos e seu uso.
ATE274512T1 (de) Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten
KR940006590A (ko) 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물
AR008272A1 (es) Derivados de piperidina 1,4-disustituida que contienen fluor, composicion farmaceutica compuesta de los mismos y un proceso para su preparacion
NO306237B1 (no) Anvendelse av xantinderivater som antidepressive midler
ATE63742T1 (de) Chinazolinon-derivate.
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
PT93066A (pt) Processo para a preparacao de derivados heterociclicos contendo nucleos bengenicos fundidos com nucleos monoazotados substituidos e de composicoes farmaceuticas que os contem
DK0572635T3 (da) Hidtil ukendte forbindelser med guanidinstruktur og farmaceutisk komposition indeholdende forbindelserne
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
ES2051834T3 (es) El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad.
AR016384A1 (es) Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta.
AR007088A1 (es) 2,4-diaminopirimidinas sustituidas, compuestos intermedios utilizados en su preparacion, procedimiento para la preparacion de dichas 2,4-diaminopirimidinas sustituidas, medicamentos que las contienen y empleos de dichas pirimidinas
AR010899A1 (es) Oxazolidinonas, un procedimiento para su preparacion, el empleo de las mismas para preparar un medicamento, medicamentos y preparaciones farmaceuticasque las contienen y un procedimiento para obtener estas preparaciones farmaceuticas.
AR039391A1 (es) Compuesto de ciclopenteno, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
HUP0300295A2 (hu) Helyettesített benzamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR044869A1 (es) Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion
NO164593C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbamat- eller urea-derivater.